A case report of euglycemic ketoacidosis due to dapagliflozin treatment
- Resource Type
- article
- Authors
- Murat Çalapkulu; Muhammed Erkam Sencar; İlknur Öztürk Ünsal; Hayri Bostan; Erman Çakal
- Source
- Turkish Journal of Internal Medicine, Vol 3, Iss Supplement 1, Pp 85-86 (2021)
- Subject
- dapagliflozin
sodium-glucose co-transporter 2 inhibitors
euglycemic ketoacidosis
Medicine
- Language
- English
- ISSN
- 2687-4245
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.